-
1 Comment
Hunan Hansen Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 3.9% below its 200 day moving average.
From a valuation standpoint, the stock is 61.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
Hunan Hansen Pharmaceutical Co., Ltd's total revenue rose by 4.2% to $210M since the same quarter in the previous year.
Its net income has increased by 0.4% to $32M since the same quarter in the previous year.
Finally, its free cash flow grew by 10.1% to $69M since the same quarter in the previous year.
Based on the above factors, Hunan Hansen Pharmaceutical Co., Ltd gets an overall score of 4/5.
| ISIN | CNE100000PK2 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | SHE |
| CurrencyCode | CNY |
| Market Cap | 3B |
|---|---|
| Target Price | None |
| PE Ratio | 16.91 |
| Beta | 0.33 |
| Dividend Yield | None |
Hunan Hansen Pharmaceutical Co., Ltd. produces and sells traditional Chinese preparations in China and internationally. It provides medicines in injection, mixture, tablet, capsule, granule, syrup, decoction, tincture, and pill forms. Hunan Hansen Pharmaceutical Co., Ltd. was founded in 1998 and is based in Yiyang, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002412.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
